Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) of the Breast (TaCe)

NCT06214793 is registered in ClinicalTrials.gov with Megan Kruse, MD as lead sponsor.

NCT NCT06214793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06214793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) of the Breast (TaCe)
Lead sponsor
Megan Kruse, MD
Phase
Phase 2
Overall status
Suspended
Start date
October 31, 2026
Completion date
January 1, 2030
Enrollment
61 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic breast cancer